Novartis Baltics

?? Today is Lipoprotein(a) Awareness Day – do you know what it is and why it is important? Lipoproteins are particles in your blood that carry cholesterol and other fats. Lp(a) can increase the risk of cardiovascular diseases (#CVD), including heart attack and stroke. Elena Kleiziene, our Cardiology Therapy Area Lead in Lithuania, says: “Approximately 1 in 5 people worldwide have elevated levels of Lp(a) in their blood. While there is currently no specific treatment for elevated Lp(a) levels, being aware of your Lp(a) levels empowers you and your doctor to effectively manage your overall cardiovascular disease risk. It is important to check your Lp(a) levels if: - You have had a premature cardiovascular event (myocardial infarction, ischemic stroke or peripheral artery disease) before the age of 55 if you’re male, or 65 if you’re female. ???????? - You have suffered a recent cardiovascular event in the last 12 months.? ?? It is recommended that every adult undergo the Lp(a) test at least once in their lifetime. ??” Considering that cardiovascular disease is the number one killer in the Baltics, we extend our heartfelt gratitude to patient organizations: - ?irdies nepakankamumu sergan?i?j? asociacija, Lietuvos ?irdies Asociacija in Lithuania - ParSirdi.lv / Inese Maurina in Latvia and all other advocates for their unwavering support in raising awareness, improving treatment options, and enhancing the patient journey. Together, we can make a difference! ?? #LipoproteinA #CardiovascularHealth #AwarenessDay #NovartisBaltics

The Time is Now to shift from Health IN All Policies to Health FOR All Policies! ???? The Health for All Policies approach recognizes that strengthening health policies and improving health outcomes have major and tangible co-benefits for other sectors. Investing in the resilience of health systems is key for country’s economy and security.* At #Novartis, we work every day to improve and extend lives of people across the #Baltics, because healthier societies are more productive, resilient, and prosperous.** Every Novartis associate in the Baltics annually: - Extends people’s lives by 52 years ?? - Brings along 7 more jobs across the value chain ?? - Contributes EUR 657,000 to the national GDP across the value chain ?? Let’s commit to an innovation-friendly ecosystem, predictable legislation, and enduring financing to maximize healthcare impact for the sustainable development of our societies! ?? #EconomicGrowth #HealthForAll #SustainableDevelopment *Source: from Health in All Policies to Health for All Policies, Greer, Scott L et al. The Lancet Public Health, Volume 7, Issue 8, e718 - e720 **Source: Experts' call to action: How strengthening health can help struggling economies grow again. February 13, 2025. Accessed February 25, 2025. https://lnkd.in/dzAD7VVd

At Novartis, we believe that collaboration drives innovation! We are thrilled to continue our partnership with the Health Tech Accelerator?in Lithuania as we enter Season 3! ?? This year, we are committed to supporting start-ups that are shaping the future of personalized medicine to improve patient journey. Through mentorship, industry expertise, and guidance in product development, we are helping founders navigate the complex journey of bringing innovative healthcare initiatives to life. Migl? Jankauskait?, a second-year mentor for the Health Tech Accelerator, shares her thoughts on our partnership: ?True healthcare innovation thrives in the right environment—Health Tech Accelerator is the catalyst that brings bold ideas to life, forging vital connections and providing the essential tools to transform vision into impact.“ We are excited to continue empowering healthcare innovation and driving patient-centric solutions together! #Novartis #HealthTechAccelerator #personalizedmedicine #ThriveTogether

#AccelerateAction to close women's health gap! Over the past 200 years, the increase in life expectancy for both men and women has been a remarkable achievement. Enhancing women's health not only drives economic benefits but, more importantly, it is a matter of health equity and inclusivity. Irēna Teterina, Head of Medical Baltics and Ukraine, explains: "Only 5% of the global health burden comes from women-specific conditions, with 95% due to conditions like heart disease, colon cancer, and autoimmune diseases that affect women differently. Improving women's health boosts economic outcomes, enhances societal well-being, benefits future generations, and promotes healthy aging. Moreover, there is a moral imperative to close the women's health gap." Barriers to access persist, despite universal health coverage in the Baltic countries. A renewed focus on primary care and prevention is one important way to simultaneously improve accessibility and efficiency. #NovartisTogether #IWD2025

?? Today, on the Rare Disease Day, we stand united with the 300 million people worldwide living with a rare disease.* A disease is classified as rare if it affects fewer than 5 in 10,000 people.* The lack of scientific knowledge and reliable information about these diseases often leads to delays in diagnosis. ? Cell and gene therapies have the potential to treat these diseases with significant unmet medical needs. We extend our heartfelt gratitude ?? to patient organizations, advocates, and other support systems for their unwavering dedication and help in the battle against rare diseases. At #Novartis, we believe that ensuring equitable and accessible treatment for those in need is essential. We are committed to bringing new treatments and hope to rare disease patients because everyone deserves a chance at a healthier life. ?? #NovartisBaltics #RareDisease #CellTherapy #GeneTherapy #RadioligandTherapy *Source: Nguengang Wakap, S., Lambert, D.M., Olry, A. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 28, 165–173 (2020). https://lnkd.in/ey-UaynS

Baltic team driven to address healthcare inequities to #ThriveTogether! ???? Last week, we welcomed the #proudtobeECC leadership team to Tallinn, Estonia, to discuss how we can amplify and expand collaborations with healthcare system partners to ensure patient access and improve health outcomes. Special thanks to Sweta Ghelani, Vivian Hernandez, and Nuria Jornet for your contributions! ?? Lauciuviene Ramune, Country President Baltics, shared: “It is always special to hear about the patients' journeys, and I would like to thank Dr Anu Hedman for her story, reminding us why we #ReimagineMedicine. The visit has truly inspired us and reignited our commitment to reaching ambitious goals for the years to come. Together, we are more determined than ever to push the boundaries of what is possible and to prioritize our patients in everything we do.” Karin Varrak, Country Business Head Estonia, added: “I would like to extend our gratitude to e-Estonia for showcasing a new benchmark, as every government service in Estonia is now fully digital, making?life simpler and better for our citizens. We will continue to explore innovative and digital solutions and partner with ecosystem stakeholders to ensure better access and outcomes for everyone! Thank you Kadi-Liis Veiman and Anni Lepland of the Estonian Cancer Center, Andrei B. of the Estonian Genome Center and Dmytro Fishman of the Better Medicine for sharing your inspirational work and possibilities to collaborate to improve and extend lives of patients.”

?????? Happy Independence Day, Estonia! Today, we celebrate the spirit of freedom, resilience, and unity that defines this beautiful nation. At #NovartisBaltics, we are proud to be a part of Estonia's journey towards innovation and excellence in healthcare. Together, we are committed to improving lives and making a positive impact on the health and well-being of our communities. ?? Let's honor the past, celebrate the present, and look forward to a healthy and bright future! #EstoniaIndependenceDay #ProudToBeBaltic

In Latvia, we are empowering breast cancer and multiple sclerosis patients to take ownership of their health journey! ?? Together with Paula Stradi?a Klīniskā universitātes slimnīca and Longenesis, we are excited to launch an innovative web-based platform that offers personalized education, automated reminders, and patient feedback collection to support adherence, monitor treatment outcomes, and enhance patient care. Highlighting public-private collaboration in innovation, hospital, Longenesis, and Novartis Baltics signed a joint project memorandum. We extend our heartfelt gratitude ?? to our speakers, including The Ministry of Health of the Republic of Latvia, Artjoms Ursulskis, project healthcare leaders - Assoc. Prof. Arvids Irmejs and Dr. Alīna Flintere-Flinte, patient advocates "Par Dzīvot" and "Mana MS", and industry experts for emphasizing the power of public-private partnerships in driving meaningful change. What does this mean for patients, healthcare professionals, and the healthcare system? ? The innovative web-based platform supports patients with personalized educational materials and automated reminders, ensuring they stay on track with prescribed therapy, routine medical tests, healthcare provider visits, and lifestyle recommendations. ? Systematic collection of Patient-Reported Outcome Measures (PROMs) enables data-driven decision-making and improved care. ? Improved adherence and stronger communication between healthcare professionals and patients. Together, we are redefining patient support and care! ?? #NovartisBaltics #PublicPrivate #DigitalHealth #PatientEmpowerment

At #NovartisBaltics, our commitment to #ESG (Environmental, Social, and Governance) is at the very core of what we do - creating long-term value for our communities by improving and extending people's lives! ????? We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in research and development, as well as novel access approaches.?

?? Today is World Cancer Day, and we stand united in the fight against breast cancer, the most common cancer worldwide. Our priority at #Novartis over the past 35 years, and looking forward, is to deliver treatments to those diagnosed with metastatic breast cancer and to advance ongoing research into treatment options for those with early breast cancer. Radvil? Jankut?, our Customer Experience Partner for Oncology in Lithuania and Early Breast Cancer Advocate within the Europe Central Cluster, says: "Breast cancer is the most common cancer among women, affecting approximately 1 in 8 during their lifetime. Thanks to today’s innovative treatments, early detection can lead to a cure when the cancer is caught early. Mammograms are an effective tool for early breast cancer diagnosis, and my dream is to see a 100% screening rate across the Baltics. ?? Your health is in your hands - schedule your screening today!" ?? Find information about breast cancer screening in the Baltics here: Lithuania: https://lnkd.in/dB3kJVd9 Latvia: https://lnkd.in/dfU7N3um Estonia: https://lnkd.in/d3bTFWWN Don't wait. Go for screening and encourage your loved ones to do the same. ?? #NovartisBaltics #WorldCancerDay #BreastCancerAwareness #EarlyDetection